Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE
Alimentary Pharmacology & Therapeutics2013Vol. 38(10), pp. 1236–1247
Citations Over TimeTop 10% of 2013 papers
Remo Panaccione, J F Colombel, William J. Sandborn, Geert D’Haens, Qian Zhou, P Pollack, Roopal Thakkar, Anne Robinson
Abstract
Prolonged adalimumab therapy maintained clinical remission and response in patients with moderately to severely active Crohn's disease for up to 4 years. No increased risk of adverse events or new safety signals were identified with long-term maintenance therapy. (clinicaltrials.gov number: NCT00077779).
Related Papers
- → A145 EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMIZED PHASE 3 STUDY(2022)3 cited
- → FRI0165 A prediction tool for drug monitoring of adalimumab in rheumatoid arthritis.(2013)
- 강직성 척추염 환자에서 Adalimumab 치료 후 관찰된 천장관절염의 회복 1예 Running title: 강직성 척추염에서 Adalimumab 치료와 천장관절염의 회복(2012)
- → Summary of Research: Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial(2023)
- → Efficacy and safety of intravenous ustekinumab re-induction therapy in Crohn’s disease patients with secondary loss of response during ustekinumab maintenance therapy: week 16 results from the phase 3b POWER trial(2023)